Paper32397643
Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.
Encinar JA and 1 other. Viruses, 2020. Cited by 78 papers, by iCite.
Cite this record
ConductScience Library. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. Papers, record 32397643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32397643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Betacoronavirus | Major topic |
| Coronavirus Infections | Major topic |
| Immune Evasion | Major topic |
| Pneumonia, Viral | Major topic |
| RNA Processing, Post-Transcriptional | Major topic |
| RNA, Viral | Major topic |
| COVID-19 | |
| Drug Repositioning | |
| Humans | |
| Immunity, Innate | |
| Methylation | |
| Models, Molecular | |
| Pandemics | |
| SARS-CoV-2 | |
| COVID-19 Drug Treatment |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SAF2016-80639-P | Ministerio de Ciencia e Innovación | International | PubMed | |
| AGL2015-67995-C3-R-1-R | Ministerio de Economía, Industria y Competitividad, Gobierno de España | International | PubMed | |
| PROMETEO/2016/006 | Generalitat Valenciana | International | PubMed |
Source PubMed
References160
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24121756 | Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients. | J Acquir Immune Defic Syndr | 2014 | https://conductscience.org/library/papers/24121756 | PubMed |
| 2 | 27510546 | Calculating protein-ligand binding affinities with MMPBSA: Method and error analysis. | J Comput Chem | 2016 | https://conductscience.org/library/papers/27510546 | PubMed |
| 3 | 30866804 | CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? | J Headache Pain | 2019 | https://conductscience.org/library/papers/30866804 | PubMed |
| 4 | 32217835 | Clinical and immunological features of severe and moderate coronavirus disease 2019. | J Clin Invest | 2020 | https://conductscience.org/library/papers/32217835 | PubMed |
| 5 | 26036224 | In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance. | Antiviral Res | 2015 | https://conductscience.org/library/papers/26036224 | PubMed |
| 6 | 27845890 | Virus inactivation under the photodynamic effect of phthalocyanine zinc(II) complexes. | Z Naturforsch C J Biosci | 2017 | https://conductscience.org/library/papers/27845890 | PubMed |
| 7 | 23115556 | Brain neuropeptides in central ventilatory and cardiovascular regulation in trout. | Front Endocrinol (Lausanne) | 2012 | https://conductscience.org/library/papers/23115556 | PubMed |
| 8 | 30879200 | Understanding CGRP and Cardiovascular Risk. | Handb Exp Pharmacol | 2019 | https://conductscience.org/library/papers/30879200 | PubMed |
| 9 | 26769332 | A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. | J Dermatolog Treat | 2016 | https://conductscience.org/library/papers/26769332 | PubMed |
| 10 | 32104915 | The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. | J Med Virol | 2020 | https://conductscience.org/library/papers/32104915 | PubMed |
| 11 | 29681484 | Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B. | Bioorg Med Chem | 2018 | https://conductscience.org/library/papers/29681484 | PubMed |
| 12 | 21666860 | Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. | ACS Med Chem Lett | 2011 | https://conductscience.org/library/papers/21666860 | PubMed |
| 13 | 21245900 | 2 methylate or not 2 methylate: viral evasion of the type I interferon response. | Nat Immunol | 2011 | https://conductscience.org/library/papers/21245900 | PubMed |
| 14 | 32292689 | Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. | Acta Pharm Sin B | 2020 | https://conductscience.org/library/papers/32292689 | PubMed |
| 15 | 30546014 | Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/30546014 | PubMed |
| 16 | 28183697 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). | Cancer Discov | 2017 | https://conductscience.org/library/papers/28183697 | PubMed |
| 17 | 30806710 | Janus kinases to jakinibs: from basic insights to clinical practice. | Rheumatology (Oxford) | 2019 | https://conductscience.org/library/papers/30806710 | PubMed |
| 18 | 32196083 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/32196083 | PubMed |
| 19 | 31995857 | Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31995857 | PubMed |
| 20 | 31821750 | Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants. | Clin Pharmacol Drug Dev | 2020 | https://conductscience.org/library/papers/31821750 | PubMed |
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41550643 | Assay development and screening of inhibitors targeting the SARS-CoV-2 2'-O-methyltransferase NSP16. | Pharm Sci Adv | 2025 | https://conductscience.org/library/papers/41550643 | PubMed |
| 41286599 | OMetaNet: an efficient hybrid deep learning model based on multimodal data fusion and contrastive learning for predicting 2'-O-methylation sites in human RNA. | BMC Bioinformatics | 2025 | https://conductscience.org/library/papers/41286599 | PubMed |
| 40969755 | Immuno-epigenetic paradigms in coronavirus infection. | Front Immunol | 2025 | https://conductscience.org/library/papers/40969755 | PubMed |
| 40697650 | Epitranscriptomic Modulation of TET2 Inhibition Suppressed SARS-CoV-2 Infection and Blocked Viral Nucleocapsid Protein in Induced-Pluripotent-Stem-Cell-Derived Cardiomyocyte Screening Models. | Biomater Res | 2025 | https://conductscience.org/library/papers/40697650 | PubMed |
| 40291443 | In silico drug repurposing of potential antiviral inhibitors targeting methyltransferase (2'-O-MTase) domain of Marburg virus. | In Silico Pharmacol | 2025 | https://conductscience.org/library/papers/40291443 | PubMed |
| 40206865 | The detection, function, and therapeutic potential of RNA 2'-O-methylation. | Innov Life | 2025 | https://conductscience.org/library/papers/40206865 | PubMed |
| 39553294 | Can the use of iron phthalocyanine-derivative mouthrinses in COVID-19 patients provide systemic benefits? Research into this potential should be considered. | GMS Hyg Infect Control | 2024 | https://conductscience.org/library/papers/39553294 | PubMed |
| 39155972 | In silico analysis of balsaminol as anti-viral agents targeting SARS-CoV-2 main protease, spike receptor binding domain and papain-like protease receptors. | In Silico Pharmacol | 2024 | https://conductscience.org/library/papers/39155972 | PubMed |
| 38969340 | Structural and functional insights into the 2'-O-methyltransferase of SARS-CoV-2. | Virol Sin | 2024 | https://conductscience.org/library/papers/38969340 | PubMed |
| 38924058 | Meta-2OM: A multi-classifier meta-model for the accurate prediction of RNA 2'-O-methylation sites in human RNA. | PLoS One | 2024 | https://conductscience.org/library/papers/38924058 | PubMed |
| 38675143 | Characterization of Plant-Derived Natural Inhibitors of Dipeptidyl Peptidase-4 as Potential Antidiabetic Agents: A Computational Study. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38675143 | PubMed |
| 38402266 | Kinetic characterization of human mRNA guanine-N7 methyltransferase. | Sci Rep | 2024 | https://conductscience.org/library/papers/38402266 | PubMed |
| 38400997 | Epigenetic modulation of myeloid cell functions in HIV and SARS-CoV-2 infection. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/38400997 | PubMed |
| 38035086 | The role of post-transcriptional regulation in SARS-CoV-2 infection and pathogenicity. | Front Immunol | 2023 | https://conductscience.org/library/papers/38035086 | PubMed |
| 36949176 | Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing. | Sci Rep | 2023 | https://conductscience.org/library/papers/36949176 | PubMed |
| 36913345 | Identification of host genomic biomarkers from multiple transcriptomics datasets for diagnosis and therapies of SARS-CoV-2 infections. | PLoS One | 2023 | https://conductscience.org/library/papers/36913345 | PubMed |
| 36911232 | Population-based virucidal phthalocyanine gargling/rinsing protocol to reduce the risk of coronavirus disease-2019: a community trial. | GMS Hyg Infect Control | 2022 | https://conductscience.org/library/papers/36911232 | PubMed |
| 36858323 | Insight into the mechanisms of coronaviruses evading host innate immunity. | Biochim Biophys Acta Mol Basis Dis | 2023 | https://conductscience.org/library/papers/36858323 | PubMed |
| 36551587 | Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36551587 | PubMed |
| 36366355 | Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/36366355 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32397643
GET https://conductscience.org/api/papers/v1/32397643/references?page=2